The Fibrolamellar Cancer Foundation (FCF) is dedicated to funding research to find viable treatment options and a cure for fibrolamellar carcinoma. FCF is an IRS approved 501 (c) (3) tax deductible public charity (EIN #27-0341021). FCF accepts grants from the largest DAF sponsor organizations and their philanthropic services teams in the United States.
Clients of BNY Mellon, Fidelity Charitable and Schwab Charitable can make a designation through the DAF Direct window below: